Pharmacological Treatment of Adolescent Major Depression

Journal of Child and Adolescent Psychopharmacology

Volumn 14, Issue 1, 2004, Pages 19-31

  Cohen, David ^a,d   Gerardin, Priscille ^a   Mazet, Philippe ^a   Purper Ouakil, Diane ^b   Flament, Martine F ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c UNIVERSITY OF OTTAWA   (Canada)

^d CIIU Pitie Salpetrere ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AKATHISIA; ANXIETY; BRUISING; CARDIOTOXICITY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DIAPHORESIS; DIZZINESS; DROWSINESS; DRUG EFFICACY; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOMANIA; HYPOTENSION; IMPOTENCE; INSOMNIA; MAJOR DEPRESSION; MANIA; MEDLINE; MOOD DISORDER; NAUSEA; PSYCHOPHARMACOLOGY; PSYCHOSIS; RASH; RESTLESSNESS; REVIEW; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUDDEN DEATH; SUICIDAL BEHAVIOR; TREMOR; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; RANDOMIZED CONTROLLED TRIALS;

EID: 1942539212     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454604773840454     Document Type: Review

References (82)

1. Alderman J, Wolkow R, Chung M, Johnston HF: Sertraline treatment of children and adolescents with obsessive compulsive disorder or depression: Pharmacokinetics, tolerability, and efficacy. J Am Acad Child Adolesc Psychiatry 37:386-394, 1998.
2. Ambrosini PJ, Wagner KD, Biederman J, Glick I, Tan C, Elia J, Hebeler JR, Rabinovich, Lock J, Geller D: Multicenter open-label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolesc Psychiatry 38:566-572, 1999.
3. American Academy of Child and Adolescent Psychiatry: Practice parameters for assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry 37(10 Suppl):63S-83S, 1998.
4. Apter A, Ratzoni G, King RA, Weizman A, Iancu I, Binder M, Riddle MA: Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression. J Am Acad Child Adolesc Psychiatry 33:342-348, 1994.
5. Basquin M, Cohen D: Les psychothérapies de la dépression avant 20 ans. In: La Dépression Avant 20 Ans. Paris, Masson, 1998.
6. Beardslee WR, Hoke L, Wheelock I, Rothberg PC, van de Velde P, Swathing S: Initial findings on preventive intervention for families with parental affective disorders. Am J Psychiatry 149: 1335-1340, 1992.
7. Bender B, Milgrom H, Rand C, Ackerson L: Psychological factors associated with medication non-adherence in asthmatic children. J Asthma 35: 347-353, 1998.
8. Bernstein GA, Anderson LK, Hektner JM, Realmuto G: Imipramine compliance in adolescents. J Am Acad Child Adolesc Psychiatry 39:284-291, 2000.
9. Biederman J, Mick E, Spencer TJ, Wilens TE, Faraone SV: Therapeutic dilemmas in the pharmacotherapy of bipolar depression in the young. J Child Adolesc Psychopharmacol 10:185-192, 2000.
10. Birmaher B, Brent DA, Kolko D, Baugher M, Bridges J, Holder D, Iyengar S, Ulloa RE: Clinical outcome after short-term psychotherapy for adolescents with major depressive disorder. Arch Gen Psychiatry 57:29-36, 2000.
11. Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE, Perel J, Nelson B: Childhood and adolescent depression: A review of the past ten years. Part I. J Am Acad Child Adolesc Psychiatry 35:1427-1439, 1996.
12. Birmaher B, Waterman GS, Ryan ND, Perel J, McNabb J, Balach L, Beaudry MB, Nasr FN, Karambelkar J, Elterich G, Quintana H, Williamson DE, Rao U: Randomized, controlled trial of amitriptyline versus placebo for adolescents with treatment-resistant major depression. J Am Acad Child Adolesc Psychiatry 37:527-535, 1998.
13. Black IB, Handry LA, Iversen LL: Trans-synaptic regulation of growth and development of adrenergic neurons in a mouse sympathetic ganglion. Brain Res 24:229-240, 1971.
14. Boulos C, Kutcher S, Gardner D, Young E: An open naturalistic open trial of fluoxetine in adolescents and young adults with treatment-resistant major depression. J Child Adolesc Psychopharmacol 2:103-111, 1992.
15. Braconnier A, Le Coent R, Cohen D; DEROXADO Study Group: Paroxetine versus clomipramine in adolescents with severe major depression: A double-blind, randomized, multicenter trial. J Am Acad Child Adolesc Psychiatry 42:22-29, 2003.
16. Brent DA, Holder D, Kolko D, Birmaher B, Baugher M, Roth C, Iyengar S, Johnson BA: A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive treatments. Arch Gen Psychiatry 54:877-885, 1997.
17. Briggs RS, Petersen MM, Cook PJ: Muscarinic agonist receptor subtypes in aging rat brain. Neurobiol Aging 3:259-261, 1982.
18. Brophy B: Kindergarteners in Prozac nation. US News and World Report. November 13, 1995, pp 96-97.
19. Burns BJ: Mental health service use by adolescents in the 1970s and 1980s. J Am Acad Child Adolesc Psychiatry 30:144-150, 1991.
20. Clarke GN, Hawkins W, Murphy M, Sheeber LB, Lewinshon PM, Seeley JR: Targeted prevention of unipolar depressive disorder in an at-risk sample of high school adolescents: A randomized trial of group cognitive intervention. J Am Acad Child Adolesc Psychiatry 34:312-321, 1995.
21. Cohen D, Flament M, Taieb O, Thompson C, Basquin M: Electroconvulsive therapy in adolescents: Ethical issues. Eur Child Adolesc Psychiatry 14:1-6, 2000.
22. Colle LM, Belair JF, Difero M, Weiss J, LaRoche C: Extended open-label fluoxetine treatment of adolescents with major depression. J Child Adolesc Psychopharmacol 4:225-232, 1994.
23. Committee on Safety of Medicines. Safety of Seroxat (paroxetine) in children and adolescents under 18 years - Contraindication in the treatment of depressive illness. www.mhra.gov.uk/. Accessed June 10, 2003.
24. Costello EJ, Bums BJ, Angold A, Leaf PJ: How can epidemiology improve mental health services for children and adolescents? J Am Acad Child Adolesc Psychiatry 32:1106-1113, 1993.
25. Cromer BA, Tarnowski KJ: Noncompliance in adolescents: A review. J Dev Behav Pediatr 10: 207-215, 1989.
26. Dugas M, Mouren MC, Halfon O, Moron P: Treatment of childhood and adolescent depression with mianserin. Acta Psychiatr Scand Suppl 320:48-53, 1985.
27. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown-Nilson M, Jacobson JG: Fluoxetine for acute treatment of depression in children and adolescents: A placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205-1215, 2002.
28. Emslie GJ, Mayes TL: Depression in children and adolescents. A guide to diagnosis and treatment. CNS Drugs 11:181-189, 1999.
29. Emslie GJ, Mayes TL, Hughes CW: Update in the pharmacologic treatment of childhood depression. Psychiatr Clin North Am 23:813-835, 2000.
30. Emslie GJ, Rush J, Weinberg WA, Kovatch RA, Hughes CW, Carmody T, Rintelmann J: A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry 54:1031-1037, 1997.
31. Esman AH: A developmental approach to the psychotherapy of adolescents. Adolesc Psychiatry 12:119-133, 1985.
32. Firth MT: An evaluation of the effectiveness of psychiatric treatment on adolescent in-patients and out-patients. Acta Paedopsychiatr 55:127-133, 1992.
33. Flament M, Cohen D: Childhood obsessive-compulsive disorders. In: Obsessive-Compulsive Disorder: Evidence and Practice. Edited by Maj M, Sartorius N. Geneva, World Psychiatric Association, 2000, pp 147-183.
34. Flament MF, Cohen D, Choquet M, Jeammet Ph, Ledoux S: Phenomenology, psychosocial correlates, and treatment seeking in major depression and dysthymia in adolescence. J Am Acad Child Adolesc Psychiatry 40:1070-1078, 2001.
35. Fleming JE, Offord DR: Epidemiology of childhood depressive disorders: A critical review. J Am Acad Child Adolesc Psychiatry 29:571-580, 1990.
36. Ford T, Goodman R, Meltzer H: The British Child and Adolescent Mental Health Survey 1999: The prevalence of DSM-IV disorders. J Am Acad Child Adolesc Psychiatry 42:1203-1211, 2003.
37. Garrison CZ, Waller JL, Cuffe SP, McKeown RE, Addy CL, Jackson KL: Incidence of major depressive disorder and dysthymia in young adolescents. J Am Acad Child Adolesc Psychiatry 36:458-465, 1997.
38. Geller B, Cooper TB, Graham DL, Fetner HH, Marsteller FA, Wells JM: Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder. J Am Acad Child Adolesc Psychiatry 31:34-44, 1992.
39. Geller B, Cooper TB, Graham DL, Marsteller FA, Bryant DM: Double-blind placebo-controlled study of nortriptyline in depressed adolescents using a "fixed plasma level" design. Psychopharmacol Bull 26:85-90, 1990.
40. Ghazziuddin N, Maylor MW, King CA: Fluoxetine in tricyclic refractory depression in adolescents. Depression 2:287-291, 1995.
41. Goldman-Rakic PS, Brown RM: Postnatal development of monoamine content and synthesis in the cerebral cortex of rhesus monkeys. Brain Res 256:339-349, 1982.
42. Hack S, Chow B: Pediatric psychotropic medication compliance: A literature review and researchbased suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol 11: 59-67, 2001.
43. Hoenigl D, Kriechbaum N, Zidek D: Mirtazapine treatment of adolescents with major depression. Hamburg (Germany), European Society of Child and Adolescent Psychiatry Meeting, 1999 (abstract).
44. Hughes CW, Emslie GJ, Crismon L, Wagner KD, Birmaher B, Geller B, Pliszka SR, Ryan ND, Strober M, Trivedi MH, Toprac MG, Sedillo A, Llana ME, Lopez M, Rush AJ: The Texas Children's medication algorithm project: Report of the Texas consensus conference panel on medication treatment of childhood major depressive disorder. J Am Acad Child Adolesc Psychiatry 38:1442-1454, 1999.
45. Karasu TB: The specificity versus nonspecificity dilemma: Toward identifying therapeutic change agents. Am J Psychiatry 143:687-695, 1986.
46. Kashani JH, Carlson GA, Beck NC, Hoeper EW, Corcoran CM, McAllister JA, Fallahi C, Rosenberg TK, Reid JC: Depression, depressive symptoms, and depressed mood among a community sample of adolescents. Am J Psychiatry 144: 584-589, 1987.
47. Katz P: The first few minutes: The engagement of the difficult adolescent. Adolesc Psychiatry 17:69-81, 1990.
48. Keller MB, Ryan ND, Strober M, Klein RG, Kutcher S, Birmaher B, Hagino O, Koplewicz H, Carlson GA, Clarke G, Emslie G, Feinberg D, Geller B, Kusumakar V, Papatheodorou G, Sack WH, Sweeney M, Wagner KD, Weller E, Winters N, Oakes R, McCafferty JP: Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. J Am Acad Child Adolesc Psychiatry 40:762-772, 2001.
49. Klein R, Mannuzza S, Koplewicz H, Tancer N, Shah M, Liang V, Davies M: Adolescent depression: Controlled desipramine treatment and atypical features. Depress Anxiety 7:15-31, 1998.
50. Kramer A, Feiguine R: Clinical effects of amitriptyline in adolescent depression: A pilot study. J Am Acad Child Psychiatry 20:636-644, 1981.
51. Kruesi MJP, Lelio DF: Disorders of conduct and behavior. In: Diagnosis and Psychopharmacology of Childhood and Adolescent Disorders. Edited by Wiener JM. New York, Wiley & Sons, 1996, pp 402-447.
52. Krupnick JL, Sotski SM, Simmens, Moyer J, Elkin I, Watkins J, Pilnokis P: The role of the therapeutic alliance in psychotherapy and pharmacotherapy outcome: Findings in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 64:532-539, 1996.
53. Kutcher S: Practical clinical issues regarding child and adolescent psychopharmacology. Child Adolesc Psychiatr Clin N Am 9:245-260, 2000.
54. Kutcher S, Boulos C, Ward B, Marton P, Simeon J, Ferguson HB, Szalai J, Katic M, Roberts N, Dubois C, Reed K: Response to desipramine treatment in adolescent depression: A fixed-dose, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 33:686-694, 1994.
55. Kye C, Ryan N: Pharmacologic treatment of child and adolescent depression. Child Adolesc Psychiatr Clin N Am 4:261-281, 1995.
56. Kye C, Waterman S, Ryan ND, Birmaher B, Williamson DE, Iyengar S, Dachille S: A randomized controlled trial of amitriptyline in the acute treatment of adolescent major depression. J Am Acad Child Adolesc Psychiatry 35:1139-1144, 1996.
57. Leonard HL, March J, Rickler KC, Allen AJ: Pharmacology of the serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry 36:725-736, 1997.
58. Lewinsohn PM, Clarke GN, Seeley JR, Rhode P: Major depression in community adolescents: Age at onset, episode duration, and time to recurrence. J Am Acad Child Adolesc Psychiatry 33:809-818, 1994.
59. Litt IF: Know thyself: Adolescents' self-assessment of compliance behavior. Pediatrics 75:693-696, 1985.
60. Male P: Psychothérapie de L'adolescent, 2nd ed. Paris, Payot, 1980.
61. Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL: Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull 33:149-154, 1997.
62. Martin A, Kaufman J, Chamey D: Pharmacotherapy of early-onset depression: Update and new directions. Child Adolesc Psychiatr Clin N Am 9:135-157, 2000.
63. McConville BJ, Minnery KL, Sorter MT, West SA, Friedman LM, Christian K: An open study on the effects of sertraline on adolescent major depression. J Child Adolesc Psychopharmacol 6:41-51, 1996.
64. Milin R, Simeon J, Spenst W: Double-blind study of paroxetine in adolescents with unipolar major depression. Chicago, American Academy of Child and Adolescent Psychiatry and Canadian Academy of Child Psychiatry Joint Annual Meeting, 1999 (abstract).
65. Mufson L, Weissman MM, Moreau D, Garfinkel R: Efficacy of interpersonal psychotherapy for depressed adolescents. Arch Gen Psychiatry 56: 573-579, 1999.
66. Murrin LC, Gibbens DL, Ferrer JR: Ontogeny of dopamine, serotonin, and spirodecanone receptors in rat forebrain-An autoradiographic study. Brain Res 355:91-109, 1985.
67. Nordberg A: The aging of cholinergic synapses: Ontogenesis of cholinergic receptors. In: Dynamics of Cholinergic Function. Edited by Hanin I. New York, Plenum, 1986, pp 165-175.
68. Pelkonen M, Marttunen M, Aro H: Risk for depression: A 6-year follow-up of Finnish adolescents. J Affect Disord 77:41-51, 2003.
69. Puig-Antich J, Perel J, Lupatkin W, Chambers W, Trabizi MA, King J, Goetz R, Davies M, Stiller RL: Imipramine in prepubertal major depressive disorders. Arch Gen Psychiatry 44:81-89, 1987.
70. Rao U, Ryan ND, Birmaher B, Dahl RE, Kaufman J, Rao R, Nelson B: Unipolar depression in adolescents: Clinical outcome in adulthood. J Am Acad Child Adolesc Psychiatry 34:566-578, 1995.
71. Rey JM, Walter G: Half century of ECT use in young people. Am J Psychiatry 154:595-602, 1997.
72. Rey-Sanchez F, Gutierrez-Casares JR: Paroxetine in children with major depressive disorder: An open trial. J Am Acad Child Adolesc Psychiatry 36:1443-1447, 1997.
73. Riddle M, Geller B, Ryan N: Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 32:792-797, 1993.
74. Rinsley DB: Theory and practice of intensive residential treatment of adolescents. Adolesc Psychiatry 1:479-509, 1971.
75. Ryan ND, Puig-Antich J, Rabinovich H, Fried J, Ambrosini P, Meyer V, Torres D, Dachille S, Mazzie D: MAOIs in adolescent major depression unresponsive to tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 27:755-758, 1988.
76. Simeon JC, Dinicola VF, Ferguson BH, Copping W: Adolescent depression: A placebo-controlled fluoxetine study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry 14:791-795, 1990.
77. Smolen AJ, Beaston-Wimmer P, Wright LL, Lindley T, Cader C: Neurotransmitter synthesis, storage, and turnover in neonatally deafferented sympathetic neurons. Brain Res 23:211-218, 1985.
78. Strober M, Carlson G: Bipolar illness in adolescents with major depression: Clinical, genetic, and psychopharmacologic predictors in a three- to fouryear prospective follow-up investigation. Arch Gen Psychiatry 39:549-555, 1982.
79. Thoenen H, Kettler R, Saner A: Time course of the development of enzymes involved in the synthesis of norepinephrine in the superior cervical ganglion of the rat from birth to adult life. Brain Res 40:459-468, 1972.
80. U.S. Food and Drug Administration: FDA statement regarding the anti-depressant Paxil for pediatric population. FDA/Website Management Staff: June 19, 2003. www.fda.gov/cder/drug/infopage/paxil/default.htm
81. Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D; Sertraline Pediatric Depression Study Group: Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: Two randomized controlled trials. JAMA 290:1033-1041, 2003.
82. Weissman MM, Wolk S, Goldstein RB, Moreau D, Adams P, Greenwald S, Klier CM, Ryan ND, Dahl RE, Wickramaratne P: Depressed adolescents grown up. JAMA 281:1707-1713, 1999.